Key Data
Fresenius is one of the top 30 companies in Germany in terms of market capitalization. It is included in Germany's leading index, the DAX, as well as the Prime Standard Pharma & Healthcare Index, and the Dow Jones Stoxx 600 Healthcare Index. We are also listed in the Dow Jones Euro Stoxx and the FTSE Eurofirst 300 indices.
The Fresenius ordinary shares are traded on the Official Market at the stock exchanges in Frankfurt, Düsseldorf and Munich.
On May 15, 2012, Fresenius SE & Co. KGaA increased the share capital.
On April 30, 2013, Fresenius SE & Co. KGaA's capital stock amounted to 178,307,893 ordinary shares. The shares are notional no-par-value shares. Each share represents €1.00 of the capital stock.
Basic Share Information
| Ordinary share | |
| Securities code no. | 578 560 |
| Ticker symbol | FRE |
| ISIN | DE0005785604 |
| Bloomberg symbol | FRE GR |
| Reuters symbol | FREG.de |
Key Data
|
2012 |
2011 |
2010 |
2009 |
2008 |
|
| Number of shares |
178,188,260 |
163,237,336 |
162,450,090 |
161,315,376 |
161,143,734 |
| Stock exchange quotation1 in € | |||||
| High |
96.38 |
75.62 |
67.59 |
43.76 |
60.87 |
| Low |
72.07 |
59.90 |
41.80 |
27.69 |
31.93 |
| Year-end quotation |
87.10 |
71.48 |
62.75 |
43.45 |
36.23 |
| Market capitalization2 in million € |
15,520 |
11,668 |
10,301 |
7,538 |
6,270 |
| Total dividend distribution in million € |
196.03 |
155.1 |
139.7 |
121.8 |
113.6 |
| Dividend per share in € |
1.103 |
0.953 |
0.86 |
0.75 |
0.70 |
| Earings per share in € |
5.424 |
4.735 |
4.085 |
3.185 |
2.856 |
1 Xetra closing price on the Frankfurt Stock Exchange
2 Total number of ordinary shares multiplied by the respective Xetra year-end quotation on the Frankfurt Stock Exchange (ordinary and preference shares until January 28, 2011)
3 Proposal
4 Net income attributable to shareholders of Fresenius SE & Co. KGaA - adjusted for a non-taxable investment gain (€34 million) and other one-time costs (€17 million) at Fresenius Medical Care as well as for one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG (€29 million).
5 Adjusted for the effects of mark-to-market accounting of the Mandatory Exchangeable Bonds (MEB) and Contingent Value Rights (CVR)
6 Before special items relating to the acquisition of Fresenius Kabi USA (formerly APP Pharmaceuticals)
